|By PR Newswire||
|September 4, 2014 11:21 AM EDT||
IRVINE, Calif., Sept. 4, 2014 /PRNewswire/ -- ALPHAEON® Corporation, a leader in lifestyle healthcare and subsidiary of Strathspey Crown Holdings LLC, announced today that the U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug (IND) application to conduct clinical studies for EVOSYAL™, an advanced Botulinum toxin Type A neurotoxin that was acquired by ALPHAEON last October, as part of the acquisition of Evolus Inc.
"The product development team is very pleased that the research presented in the IND application was accepted by the FDA without questions, permitting the initiation of the clinical study to support safety and efficacy of this excellent product," said Del Stagg, PhD, ALPHAEON VP of Regulatory.
"EVOSYAL represents the state-of-the-art in both consistent manufacturability and potency as a 900 kDa neurotoxin molecular complex with high purity, both of which we believe will aid in achieving precise, predictable and long-lasting patient outcomes," said John Gross, MD, Chief Scientific Officer for Evolus.
"FDA acceptance of our IND and clinical program is a critical milestone towards FDA approval and a testament to the strength of ALPHAEON's clinical development team," said ALPHAEON Beauty President, J. Christopher Marmo PhD. "This approval is a key step in bringing U.S. consumers new best-in-class aesthetic products."
According to the ASPS®, Botulinum toxin Type A was injected for cosmetic purposes more than 6 million times last year, accounting for over 2 billion dollars of consumer spend annually, which was a 3 percent increase from the previous year. ALPHAEON expects the initial clinical trial to be fully enrolled by the end of 2014.
About ALPHAEON Corporation
ALPHAEON Corporation is a lifestyle healthcare company committed to partnering with board-certified physicians to bring to market and develop highly innovative technologies and services that promote patient wellness, beauty and performance. Ensuring access to leading advancements in lifestyle healthcare, the company fosters deep relationships with leading specialty physicians so patients look their best, feel their best and know they are receiving the best in lifestyle healthcare. For more information, please visit www.alphaeon.com.
About Strathspey Crown
Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. Strathspey Crown uniquely partners with board certified physician specialists to bring to market highly innovative technologies and services in the self-pay sector. The firm is founded in partnership with physician investors across three key medical specialties: plastic surgery, ophthalmology and dermatology. For more information visit www.strathspeycrown.com.
About Evolus, Inc.
Evolus Inc., founded in 2012, is headquartered in Santa Barbara, California. The company has a robust and experienced R&D team with international neurotoxin manufacturing, clinical and regulatory experience. Key management includes Chief Executive Officer J. Christopher Marmo, Ph.D., who previously led Allergan's Medical's Global R&D organization and Chief Scientific Officer John Gross, MD, who chairs the Injectable Safety Coalition. On September 30, 2013, Evolus entered a partnership with Daewoong Pharmaceuticals, the leading Korean pharmaceutical manufacturer, to manage the clinical tests and regulatory approvals of Daewoong's neurotoxin in the United States and other international markets.
Jenna Mons, Vice President of Marketing and Communications
Email: [email protected]
ALPHAEON® is a registered trademark of Strathspey Crown LLC
EVOSYAL™ is a trademark of Strathspey Crown LLC
ASPS® is a registered trademark of the American Society of Plastic Surgeons
TEOSYAL® is a registered trademark of TEOXANE
SOURCE ALPHAEON Corporation
"We are a custom software development, engineering firm. We specialize in cloud applications from helping customers that have on-premise applications migrating to the cloud, to helping customers design brand new apps in the cloud. And we specialize in mobile apps," explained Peter Di Stefano, Vice President of Marketing at Impiger Technologies, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 7, 2016 05:15 PM EST Reads: 284
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Dec. 7, 2016 05:15 PM EST Reads: 227
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Dec. 7, 2016 05:15 PM EST Reads: 1,733
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
Dec. 7, 2016 05:15 PM EST Reads: 923
Dec. 7, 2016 05:00 PM EST Reads: 1,911
Dec. 7, 2016 04:30 PM EST Reads: 1,671
Dec. 7, 2016 04:15 PM EST Reads: 779
Dec. 7, 2016 04:15 PM EST Reads: 313
Dec. 7, 2016 04:15 PM EST Reads: 321
Dec. 7, 2016 04:00 PM EST Reads: 1,270
Dec. 7, 2016 03:48 PM EST Reads: 233
Dec. 7, 2016 03:45 PM EST Reads: 2,245
Dec. 7, 2016 03:30 PM EST Reads: 1,768
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, drew together recent research and lessons learned from emerging and established compa...
Dec. 7, 2016 02:30 PM EST Reads: 939
Dec. 7, 2016 02:30 PM EST Reads: 4,309